Angelini
 | |
| Private | |
| Industry | Pharma, Personal care, Machinery, Wine, Perfumery |
| Founded | 1919 |
| Headquarters | Rome, Italy |
Key people | Francesco Angelini |
| Revenue | Approx. 1.4 Billion Euro (2013) |
Number of employees | Approx. 4000 (2013) |
| Website | www.angelinipharma.com |
Angelini is a medium-sized private international group. Born in Italy in the early twentieth century, the Angelini group has offices in 20 countries. Led by President Francesco Angelini, the group employs approximately 4000 people.[1]
History
The beginning: 1920-1940
The story of Angelini started in 1919 in a small laboratory in Ancona.[2] In 1940 ACRAF was founded, which stands for Aziende Chimiche Riunite Angelini Francesco, whose main activities are the production and distribution of drugs.[2] Immediately after the war, Francesco Angelini imported vitamin B12 into Italy, a tonic for treating anemia, a widespread disease at that time.[2] The drug is produced and marketed under the trademark Dobetin.
1950s: The turning point
At the beginning of the fifties the company expanded its operations to Rome, where the head office is now situated. During the same period, company activities were diversified and Angelini entered the field of consumer goods: 1958 saw the foundation of Fater, a Pescara based company active in the production of baby diapers and sanitary napkins. In the same year, Tachipirina was launched on the market, an anti-flu drug containing paracetamol.[2]
1960s and 1970s: "The golden age"
In 1963, in full baby boom, Fater launched the Lines brand of disposable diapers, and two years later, a line of women's sanitary towels also branded under Lines.[2] The name Lines was chosen because it recalls linen, the material used to make these sanitary towels used up to that time. In 1964, upon the death of Francesco Angelini, his son Igino takes over the management of the company. In the 60s production began for the first original molecules of Angelini pharmaceutical research. Between the sixties and seventies, molecules such as oxolamina (anti-cough), benzydamine (anti-inflammatory), trazodone (antidepressant) and dapiprazole (anti-glaucoma) were discovered.[2] In the field of production technology, in 1975 Angelini introduced machinery for manufacturing diapers and introduced the use of electronics in production lines.[2]
1980s: A modern and international company
In 1985, Angelini launched Moment, a self-medication analgesic drug against headaches with ibuprofen.[2] In the 80s, the Angelini Group began its internationalization process with the creation of manufacturing and commercial facilities in Spain and Portugal.[2] Activities on the Iberian peninsula began in 1979 with the acquisition of the Lepori group of Barcelona, consisting of three companies: Farma Lepori and L. Lepori, active in the production and marketing of drugs, and Laboratorios Ausonia, specializing in the production of talc and childcare articles.
1990s: Diversification and strategic alliances
In 1993, upon the death of Igino Angelini, his son Francesco took over and strengthened the group’s alliance established in 1992 with Procter & Gamble in the health and hygiene sector. In Italy, the American multinational company, with the international brand Pampers (baby diapers) complements Lines for women's sanitary towels, while the Lines nappy brand is licensed to another industrial group for antitrust reasons.[2] In the mid-'90s, Francesco Angelini, in view of diversifying business activities, enhanced the food group, created in the late fifties. In 1993 the group entered the market of wines, oils and cured meats.
From 2000 to today: Strengthening core business and internationalization
Since 2000, Angelini manufacturers and distributes generic drugs in Italy.[2] In that same year, Amuchina, a Genoa-based company that produces disinfectants and sanitizers, joined the Angelini Group. Between 2000 and 2001, it acquired Helsinn Produtos Farmacêuticos and Helfarma Produtos Farmacêuticos, two Portuguese pharmaceutical companies. In 2002, Angelini purchased Farmamed, a para-pharmaceutical marketing company for products sold in supermarkets and in 2003 made its entrance in the market of herbal products and supplements with the acquisition of Body Spring.[2] In 2004, in fact, the company acquired a significant stake in Elder Pharmaceuticals, a pharmaceutical company in the Indian market. In 2007 it acquired CSC Pharmaceuticals, a pharmaceutical group active in Central and Eastern Europe and Angelini's strategic partner since 1998, while in 2008 it acquired the Greek pharmaceutical group Angelini Pharma Hellas. Since 2009 Alcavis HDC LLC, a U.S. company that sells antiseptics and disinfectants, and the Pakistan based pharmaceutical company Angelini Pharmaceuticals (PVT) LTD are part of the Group. Between 2010 and 2011, the Angelini group strengthened its presence in the wine sector with the acquisition of the winery Puiatti in Friuli and the company Bertani, best known for the production of Amarone in the Verona area. In 2011 the brand Infasil was acquired from P&G.[2] In 2011, Angelini took its first steps in Turkey with the acquisition of the pharmaceutical company Angelini Ilac San. Ve Tic. In 2012, the Angelini group's product portfolio was expanded with the trademarks ACE and Neoblanc (market of products for household cleaning), acquired from Fater, while in the Perfumery sector the Group acquired a share in the company ITF, with offices in Italy and Germany.[2]
The Group
Pharma
In the Pharma area, Angelini is an integrated company with research, development, manufacture and marketing of active ingredients, and branded drugs and equivalents, medical products and dietary supplements. At the international level, Angelini is concentrated in the areas of analgesia, inflammation, neuropsychiatry, flu, diseases of the oral cavity, gynecology and disinfection. Its offices are present in 19 countries (Italy, Spain, Portugal, Austria, Poland, Czech Republic, Slovakia, Hungary, Romania, Bulgaria, Slovenia, Croatia, Germany, Greece, Russia, USA, Pakistan, India and Turkey) where it operates with about 2,600 people, including 100 researchers and a commercial structure of 1,000 individuals.[3] The most common and well-known international brands are Trittico, Tantum and Aulin. Angelini drugs are marketed through licensing and export agreements with more than sixty partners, including major multinational drug companies.[3] The most common molecules are trazodone, benzydamine and prulifloxacine, respectively antidepressant, anti-inflammatory and antibacterial, resulting of Angelini research. In 2000 the percentage of turnover generated abroad was 15%. In 2013 this number changed to approximately 50%.[3]
Personal Care
Angelini is present in the Italian market of absorbent products for personal care with Fater, since 1992 a joint venture between Angelini and Procter & Gamble, with brands such as Lines and Pampers, Linidor and Dignity, Tempo and Tampax.[3] In 2012 Fater enriched its product portfolio with the acquisition of the ACE and Neoblanc trademarks, with which it entered the market of house cleaning products.[3] Founded in 1958 by the Angelini family, Fater has its head office in Pescara and manufacturing facilities in Pescara, Campochiaro (CB) and Porto (PT). Fater employs approximately 1000 people and has a turnover of approximately 970 million Euro/year (2013).[3] It is certified under the ISO 9001 Quality System, with the ISO 14001 Environmental Management System and EMAS and under the OSHAS 18001 Management of Health and Safety at Work system.[3]
Machinery
Fameccanica is a wholly owned subsidiary of Fater, a joint venture between Angelini and Procter & Gamble. The Fameccanica plant is in Sambuceto di S. Giovanni Teatino (CH), where machinery for baby diapers and sanitary napkins for ladies are designed.[3] Today the Fameccanica group can count four companies: Fameccanica Data in Italy, Fameccanica Machinery Shanghai, Fameccanica do Brasil and Fameccanica North America.
Wine sector
Bertani Domains operates in viticulture. Today’s scene is composed of about 1,600 acres, of which 310 are vineyards with a total production of about 1.5 million bottles a year.[3] In the three historic Tuscan wineries, Bertani Domains produces wines in the three designations of origin: Brunello di Montalcino (Val di Suga in Montalcino), Vino Nobile di Montepulciano (Trerose in Montepulciano) and Chianti Classico (San Leonino Castellina in Chianti). Tenuta Collepaglia at Castelli di Jesi, produces Verdicchio dei Castelli di Jesi Classic Superior. Puiatti wineries, in Friuli, is known for its prestigious Collio and Isonzo DOC, while the company Bertani, is best known for the production of Amarone in the Valpantena, area north of Verona.[3]
Perfumery
Since 1994 Angelini is present in the creation and distribution of perfumes with the Spanish company Idesa Parfums and with the company ITF, in Italy and Germany. Idesa Parfums creates and distributes perfumes and fragrances. Established in 1963, Idesa products are present in 3000 sales outlets in Spain.[3] At the international level, the scents produced by Idesa are distributed in about 85 countries across Europe, Asia, Far East, United States, Central America and South America. Among the fragrances that Idesa has created and distributes are those of Armand Basi, Mandarina Duck, Angel Schlesser, Custo Barcelona, Joaquin Cortes, Women's Secret and the Anne Moller line of cosmetics. The company is the exclusive distributor for Spain of Versace, Moschino, DSquared2 and other perfumes.[3] In 2013, Angelini acquired shares in the Italian company ITF SpA and the entire German company ITF Germany Gmbh.[3] ITF SpA, founded in Milan in 2002, is a perfumery company that creates, develops and distributes fragrances and beauty products for brands like Blumarine, DSquared2, Pomellato and Trussardi.
Research and Development
Angelini research
Angelini developed a number of drugs. Two of these, benzydamine, an anti-inflammatory agent for topical use, and trazodone, an antidepressant, are marketed in more than 60 countries.[4] Recently Angelini acquired the fluoroquinolone prulifloxacin licence from Nippon Shinyaku.[4] Angelini Research is done at the Angelini Research Centre in Santa Palomba, Rome.
Research projects
Angelini belongs to a working group called the Italian Drug Discovery Network (IDDN), which includes both other Italian pharmaceutical companies and public research institutes. The aim of the IDDN is to promote interaction between public and private research in the identification of new pharmacologically active compounds.
Focus on therapeutic areas
Pain and Inflammation
Angelini R&D has a longstanding tradition of studies on pain and inflammation, areas that make a significant contribution to the company portfolio. The research subjects include studies on the role of prostaglandins, cytokines and serotoninergic transmission routes, in the mechanisms modulating pain and inflammation. Currently the R&D group is studying combinations of molecules or drugs active on the central nervous system that could increase their efficacy and reduce side effects. These studies also include optimization through formulative approaches in the bio availability and posology of analgesic drugs.
Central Nervous System (CNS)
The area of drugs active on the CNS, particularly drugs for mood disorders, is the field where Angelini has enjoyed the greatest successes and recognition at world level.<ref name=" Silvestrini B (1989). "Trazodone: from the mental pain to the "dys-stress" hypothesis of depression". Clin Neuropharmacol 12(Suppl 1): S4–10">Silvestrini B (1989). "Trazodone: from the mental pain to the "dys-stress" hypothesis of depression". Clin Neuropharmacol 12(Suppl 1): S4–10</ref> The introduction of the treatment of major depression into clinical practice, which happened in the USA during the Sixties and in 1981, changed the therapeutic approach to the treatment of this disease.[5] Trazodone is still used today, thanks to its broad spectrum of neurophysiopharmacological actions and its good tolerability. Angelini laboratories continue making studies on the mechanisms of action of trazodone and on new compounds active on different molecular targets in neuropsychiatric diseases. These studies deal with the problem of the mechanism responsible for the antidepressive activities following their effects on neurotransmission. Research activities are also in progress in the Angelini laboratories on new molecular targets responsible for the following pathologies of the CNS: bipolar disorder, schizophrenia, multiple sclerosis.
Infection
Starting with the experience of the development of prulifloxacin, Angelini R&D gradually became more interested in anti-infectives, an area where pharmacological research has become a priority in order to solve the serious problem of antibiotic resistance. At present, studies are being made on the efficacy of different chemical classes (small molecules, macromolecules and peptides) and of medical devices made with advanced antibiotic-resistance technologies. Angelini R&D is also working on the emerging problem of the intestinal, vaginal and dermal microbiota, its role in maintaining the state of wellness and its alterations in infectious diseases.[4]
Production Plants
The manufacturing plants of the Angelini Group are located in Ancona, Aprilia (LT) and Casella (GE). Pharmaceuticals are produced at the Ancona plant for finished products, and Aprilia for pharmaceutical raw materials, while the plant in Casella specializes in the production of Amuchina brand disinfectants. The production is destined for all worldwide markets.[6]
Financial results
Revenue per area in million EUR in 2013.[7]
Pharma: 741
Personal Care: 484
Machinery: 103
Perfumery: 77
Wine sector: 18
Real estate: 4.5
References
- ↑ About Angelini
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Angelini’s History
- 1 2 3 4 5 6 7 8 9 10 11 12 13 The Angelini Group
- 1 2 3 Angelini R&D
- ↑ / Trazodone Info – US National Library of Medicine
- ↑ Angelini Production
- ↑ Financial Results